(326 days)
No
The description details a standard pulse oximetry device based on light absorption principles, with no mention of AI or ML in the device description, performance studies, or key metrics. The focus is on the physical sensor and its sterilization method.
No
The device is described as a sensor for monitoring oxygen saturation and pulse rate, which are diagnostic and monitoring functions, not therapeutic interventions.
Yes
The device, a pulse oximeter sensor, measures arterial oxygen saturation (SpO2) and pulse rate, which are physiological parameters used in a clinical setting to assess a patient's health status. This continuous monitoring of vital signs is a form of diagnostic measurement, providing data essential for diagnosing various conditions or monitoring the progression of illness.
No
The device description explicitly details hardware components (LEDs, photo sensor, wiring system, taping system) that are essential for its function. It is a physical sensor, not solely software.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended for use in vitro for the examination of specimens, including blood and tissue samples, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to monitor therapeutic measures.
- Device Function: The described device is a pulse oximeter sensor. It measures oxygen saturation and pulse rate non-invasively by shining light through tissue (finger, foot, or hand) and analyzing the light absorption. It does not examine specimens derived from the human body in vitro.
- Intended Use: The intended use is for continuous noninvasive monitoring of arterial oxygen saturation and pulse rate. This is a direct measurement on the patient, not an analysis of a sample outside the body.
Therefore, the device falls under the category of a non-invasive physiological monitoring device, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The sensor is indicated for single patient use for continuous noninvasive arterial oxygen saturation and pulse rate monitoring.
Product codes
NLF
Device Description
In a clinical setting, a pulse oximeter sensor measures the oxygen saturation of arterial blood (SpO2). A pulse oximeter sensor is composed of a light emitting diode (LED) and a sensor that are placed on opposite sides of a patient's finger or foot. The LED contains a red light and an infrared light that are differentially absorbed by oxygenated and deoxygenated hemoglobin. Based on the relative absorption of the two wavelengths that is determined by the sensor, the POX determines the relative amount of oxygenated and deoxygenated hemoglobin, which is calculated as SpO2. In order to make the SpO2 calculation independent of skin color, finger size, etc., the pulse oximeter sensor uses only the time varying light absorption component generated by the patient's pulse. The sensor also uses the period of pulsation to measure patient pulse rate. The pulse oximeter can estimate the amount of oxygen in the blood without having to draw a blood sample.
The primary components of an oxygen transducer, or Pulse Oximeter (POX) Sensor, are light-emitting diodes (red and infrared LED) and a photo sensor. These components (with their wiring system) are embedded within a taping system designed for wrapping the POX Sensor around a patient's finger, foot, or hand so that the LED and photo sensor are directly opposite to each other. As the lights are emitted and received across a vascular bed, the rates of absorption at the two wavelengths vary depending upon the ratios of oxygenated and deoxygenated hemoglobin within the blood.
The proposed devices of this submission do not differ from the predicate device. The only difference is that the proposed devices will be exposed to vaporized hydrogen peroxide for sterilization instead of ethylene oxide.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
finger or foot, patient's finger, foot, or hand
Indicated Patient Age Range
Not Found. Neonatal indication has been removed from Max-N and N-25 models.
Intended User / Care Setting
Prescription Use, clinical setting
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To support the substantial equivalence of product performance after being sterilized by vaporized hydrogen peroxide to that of the predicate devices, non-clinical bench simulation testing was conducted using a stand-in device. The stand-in device allows for SpO2 sensor verification by passing the light source of the pulse oximeter sensor (LED) through one side of the signal transmission measured by the photocell (photo-detector) of the pulse oximeter sensor on the opposing side of the stand-in.
A functional pulse oximeter sensor when connected to a pulse oximeter console will have the ability to monitor SpO2 and Pulse Rate. Bench and laboratory testing was conducted to determine whether a pulse oximeter sensor is functional and is assessed by performing continuity and sensitivity testing. This included the following tests:
- Continuity testing to verify there are no open circuits and the current along the path of a circuit is continuous
- Sensitivity testing to detect the signal transmission between the photodiode and the LED (light emitting diode)
Additional performance testing of this submission references data submitted in previously cleared 510(k)s K042316 and K012344.
Stryker Sustainability Solutions performed the clinical validation testing of the SpO2 performance under no motion on healthy, adult volunteers in the range of 70% to 100%. The ARMS for SpO2 under no motion was found to be 1.62% and 1.56% for woven and non-woven tape, respectively, over the range of 70-100%.
The results of the non-clinical and clinical testing demonstrate that all requirements and performance specifications were satisfied and support the subject device is substantially equivalent to its predicate.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
ARMS for SpO2 under no motion was found to be 1.62% and 1.56% for woven and non-woven tape, respectively, over the range of 70-100%.
Predicate Device(s)
K042316, K012344, K012891, K993637
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.2700 Oximeter.
(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a stacked format.
March 8, 2022
Stryker Sustainability Solutions Mia Brown Senior Regulatory Affairs Specialist 1810 West Drake Drive Tempe, Arizona 85283
Re: K211138
Trade/Device Name: Reprocessed Pulse Oximeter Sensor Models: (D-25) (D-25), (D-20), (N-25), (I-20), (Max-A), (Max-AL), (Max-P), (Max-N), (Max-I). Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: NLF Dated: February 10, 2022 Received: February 11, 2022
Dear Mia Brown:
(NOTE: Reprocessed SUD device types require a separate attachment of the list of all models cleared in the submission. A corrected SE letter will be required if the attachment is omitted.)
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrl/cfdocs/cfpmn/pmn.cfm identifies.combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation -emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrl-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Todd Courtney Assistant Director DHT1C: Division of Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K21138
Device Name
Reprocessed Pulse Oximeter Sensor Models: (D-25), (D-20), (N-25), (I-20), (Max-A), (Max-AL), (Max-N), (Max-N), (Max-I).
Indications for Use (Describe)
The sensor is indicated for single patient use for continuous noninvasive arterial oxygen saturation and pulse rate monitoring.
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
As required by 21 CFR 807.92
| Contact Details | |
|---|---|
| Applicant Name | Stryker Sustainability Solutions |
| Applicant Address | 1810 West Drake Drive |
| Tempe, AZ 85283 | |
| Applicant Contact | Mia Brown |
| Applicant Contact Email | mia.brown1@stryker.com |
| Device Name | |
| Device Trade Name | Reprocessed Pulse Oximeter Sensor Models: (D-25), (D-25L), (D-20), (N-25), (I-20), (Max-A), (Max-AL), (Max-P), (Max-N), (Max-I). |
| Common Name | Oximeter |
| Classification Name | Oximeter, Reprocessed |
| Regulation Number | 870.2700 |
| Product Code | NLF |
Legally Marketed Predicate Devices
| Predicate # | Predicate Trade Name (Primary Predicate is listed first) | Product Code |
|---|---|---|
| K042316 | Vanguard Reprocessed Pulse Oximeter Sensors | NLF |
| K012344 | Vanguard Reprocessed Pulse Oximeter Sensors | NLF |
| K012891 | OxiMax Pulse Oximetry System with N-595 Pulse Oximeter and | |
| OxiMax Sensors and Cables | DQA | |
| K993637 | N-395 Pulse Oximeter, with extended device claims | DQA |
4
Device Description Summary
In a clinical setting, a pulse oximeter sensor measures the oxygen saturation of arterial blood (SpO2). A pulse oximeter sensor is composed of a light emitting diode (LED) and a sensor that are placed on opposite sides of a patient's finger or foot. The LED contains a red light and an infrared light that are differentially absorbed by oxygenated and deoxygenated hemoglobin. Based on the relative absorption of the two wavelengths that is determined by the sensor, the POX determines the relative amount of oxygenated and deoxygenated hemoglobin, which is calculated as SpO2. In order to make the SpO2 calculation independent of skin color, finger size, etc., the pulse oximeter sensor uses only the time varying light absorption component generated by the patient's pulse. The sensor also uses the period of pulsation to measure patient pulse rate. The pulse oximeter can estimate the amount of oxygen in the blood without having to draw a blood sample.
The primary components of an oxygen transducer, or Pulse Oximeter (POX) Sensor, are light-emitting diodes (red and infrared LED) and a photo sensor. These components (with their wiring system) are embedded within a taping system designed for wrapping the POX Sensor around a patient's finger, foot, or hand so that the LED and photo sensor are directly opposite to each other. As the lights are emitted and received across a vascular bed, the rates of absorption at the two wavelengths vary depending upon the ratios of oxygenated and deoxygenated hemoglobin within the blood.
The proposed devices of this submission do not differ from the predicate device. The only difference is that the proposed devices will be exposed to vaporized hydrogen peroxide for sterilization instead of ethylene oxide.
Intended Use/Indications for Use
The sensor is indicated for single patient use for continuous noninvasive arterial oxygen saturation and pulse rate monitoring.
Indications for Use Comparison
The indications for use for the subject device are the same as those of the predicate device, with the exception that the neonatal indication has been removed from the Max-N and N-25 models.
Technological Comparison
The design of the reprocessed device is the same as the predicate device. The indications for use does not change from the predicate device (K042316, K012344), with the exception that the neonatal indication has been removed from the Max-N and N-25 models. The same standard mechanical design and sizes and equivalent materials are utilized. There are no changes to the claims, clinical applications, or performance specifications.
The subject device and the predicate device have technological characteristics, i.e., they have the same:
5
- intended use;
- principle of operation;
- form factor and components;
- measurement application sites;
- performance specifications;
- environmental and mechanical specifications
Principle of Operation
The principle of operation of pulse oximetry is based upon the fundamental principle that hemoglobin bound to oxygen (oxyhemoglobin unbound to oxygen (deoxyhemoglobin) vary in the absorption of different wavelengths of the light and the absorptions can be used to estimate SpO2 and pulse rate. The mechanism by which this process occurs is the use of red and infrared wavelengths of light delivered by an emitter and the detection of the signal from the light absorption of oxygenated blood and deoxygenated blood to determine functional oxygen saturation of hemoglobin (SpO2).
Mechanism of Action for Achieving the Intended Effect
The Reprocessed Pulse Oximeter Sensor provides the intended effect equivalent to the previously cleared pulse oximeter sensor in that it utilizes an optical sensor that is applied to the patient's finger or toe through which light is transmitted to the photodetector that detects the signal transmission. The signal transmission is processed by the Pulse Oximeter to provide SpO2 and pulse rate.
Non-Clinical and/or Clinical Tests Summary & Conclusions
To support the substantial equivalence of product performance after being sterilized by vaporized hydrogen peroxide to that of the predicate devices, non-clinical bench simulation testing was conducted using a stand-in device. The stand-in device allows for SpO2 sensor verification by passing the light source of the pulse oximeter sensor (LED) through one side of the signal transmission measured by the photocell (photo-detector) of the pulse oximeter sensor on the opposing side of the stand-in.
A functional pulse oximeter sensor when connected to a pulse oximeter console will have the ability to monitor SpO2 and Pulse Rate. Bench and laboratory testing was conducted to determine whether a pulse oximeter sensor is functional and is assessed by performing continuity and sensitivity testing. This included the following tests:
-
Continuity testing to verify there are no open circuits and the current along the path of a circuit is continuous
-
Sensitivity testing to detect the signal transmission between the photodiode and the LED (light emitting diode)
Additional performance testing of this submission references data submitted in previously cleared 510(k)s K042316 and K012344.
6
All reprocessed pulse oximeter sensors materials that are normally in contact with the patient are removed and replaced with medical grade adhesive tape during reprocessing by Stryker Sustainability Solutions. The reprocessed pulse oximeter sensors meet biocompatibility requirements of ANSI/AAMI/ISO 10993-1: 2009: Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process for surface contacting devices with prolonged exposure (> 24 hours, but less than 30 days) with skin.
Clinical Testing
Stryker Sustainability Solutions performed the clinical validation testing of the SpO2 performance under no motion on healthy, adult volunteers in the range of 70% to 100%. The ARMS for SpO2 under no motion was found to be 1.62% and 1.56% for woven and non-woven tape, respectively, over the range of 70-100%.
The results of the non-clinical and clinical testing demonstrate that all requirements and performance specifications were satisfied and support the subject device is substantially equivalent to its predicate.
The subject device has the same intended use as the proposed predicate and the differences in technological features do not raise different questions of safety and effectiveness. Based on a comparison of the intended use/indications for use, technological characteristics, and performance data to the predicate devices, the subject device is equivalent to the predicate device.